Evoke Pharma
EVOK
EVOK was delisted on the 16th of December, 2025.
15 hedge funds and large institutions have $1.93M invested in Evoke Pharma in 2024 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 1 closing their positions.
2,573% more capital invested
Capital invested by funds: $72.2K → $1.93M (+$1.86M)
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
50% more funds holding
Funds holding: 10 → 15 (+5)
2.94% more ownership
Funds ownership: 0.17% → 3.11% (+2.9%)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$599K |
| 2 |
BL
Bleichroeder LP
New York
|
+$584K |
| 3 |
ACM
Altium Capital Management
New York
|
+$513K |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$478K |
| 5 |
Goldman Sachs
New York
|
+$9.54K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$1.28K |
| 2 |
Morgan Stanley
New York
|
-$272 |
| 3 |
BlackRock
New York
|
-$8 |
| 4 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$2 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ACM
1
AIGH Capital Management
Baltimore,
Maryland
| $516K | +$599K | +70,547 | New |
|
|
BL
2
Bleichroeder LP
New York
| $503K | +$584K | +68,750 | New |
|
|
ACM
3
Altium Capital Management
New York
| $442K | +$513K | +60,412 | New |
|
|
NCM
4
Nantahala Capital Management
New Canaan,
Connecticut
| $412K | +$478K | +56,250 | New |
|
5
Vanguard Group
Malvern,
Pennsylvania
| $18.2K | – | – | – |
|
6
Geode Capital Management
Boston,
Massachusetts
| $16.5K | – | – | – |
|
|
7
Goldman Sachs
New York
| $8.22K | +$9.54K | +1,123 | New |
|
8
Millennium Management
New York
| $6.63K | +$7.7K | +906 | New |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $4.52K | +$680 | +80 | +15% |
|
|
10
BlackRock
New York
| $893 | -$8 | -1 | -0.8% |
|
|
11
UBS Group
Zurich,
Switzerland
| $675 | -$1.28K | -151 | -62% |
|
|
12
Morgan Stanley
New York
| $229 | -$272 | -32 | -51% |
|
|
NA
13
NewEdge Advisors
New Orleans,
Louisiana
| $127 | – | – | – |
|
14
Wells Fargo
San Francisco,
California
| $40 | +$34 | +4 | +200% |
|
|
FDCDDQ
15
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| – | -$2 | – | – |
|
EVOK Hedge Fund Activity: Q1 2024 in Review
15 of the 6,946 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q1 2024, worth a combined $1.93M — up 2,573% from $72.2K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new EVOK positions and 1 closed out — a net gain of 5 holders — while 2 added to existing stakes and 3 trimmed.
The largest buyer was AIGH Capital Management, opening a new position worth an estimated $599K. The largest seller was UBS Group, cutting an estimated $1.28K.
- 15 institutional investors held Evoke Pharma (EVOK) as of Q1 2024, up from 10 in Q4 2023.
- Funds reported $1.93M of Evoke Pharma stock for Q1 2024, up 2,573% quarter-over-quarter.
- 6 funds opened new Evoke Pharma positions in Q1 2024 and 1 closed out, a net change of +5 holders.
- The largest Evoke Pharma buyer in Q1 2024 was AIGH Capital Management, an estimated $599K added.
- The largest Evoke Pharma seller in Q1 2024 was UBS Group, an estimated $1.28K sold.
Based on aggregated 13F filings for Q1 2024.